NCT03979508 2025-11-12Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast CancerMayo ClinicPhase 2 Terminated26 enrolled
NCT02784795 2025-08-21A Study of LY3039478 in Participants With Advanced or Metastatic Solid TumorsEli Lilly and CompanyPhase 1 Terminated94 enrolled 28 charts
NCT04256941 2024-12-27Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT StudyM.D. Anderson Cancer CenterPhase 2 Terminated4 enrolled 7 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT04305236 2023-06-06Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast CancerUniversity of California, IrvinePhase 2 Terminated1 enrolled 5 charts
NCT04031885 2021-08-24A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast CancerEli Lilly and CompanyPhase 4 Terminated4 enrolled 9 charts